Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership

Biogen Inc. (Nasdaq: BIIB) has agreed to acquire TJ Biopharma’s exclusive rights to develop and commercialize the investigational antibody felzartamab in the Greater China Region, consolidating worldwide rights to the therapy under a single owner for the first time. The deal carries an upfront payment of $100 million, with TJ Biopharma eligible for up to $750 million in commercial and sales milestone payments, bringing total potential consideration to $850 million, plus royalties in the mid-single-digit to low-double-digit percentage range on net sales in the region. The transaction completes a rights structure that Biogen began assembling when it acquired Human Immunology Biosciences in July 2024, and positions felzartamab as a genuinely global asset in the company’s immunology pipeline. Biogen stock (Nasdaq: BIIB) rose roughly 3.6% on the announcement, with shares trading around $183 on April 20, near the upper range of their 52-week band of $114.66 to $202.41.

What does Biogen’s acquisition of felzartamab rights in China mean for its global immunology strategy?

The strategic logic here is consolidation, not exploration. Biogen already held ex-China rights to felzartamab, so this transaction is less about discovering a new asset and more about eliminating the operational complexity that comes with split global rights. Running separate development, manufacturing, and commercial tracks across different partners in the world’s most populous market creates coordination friction, regulatory duplication, and potential brand inconsistency. By absorbing TJ Biopharma’s China position, Biogen gains unified control over all three of those levers simultaneously.

What makes this especially consequential is the competitive positioning of felzartamab itself. The antibody targets CD38, a protein expressed on plasma cells, plasmablasts, and natural killer cells, and has shown in clinical studies the ability to selectively deplete pathogenic antibody-producing cells. That mechanism has applications across a range of immune-mediated diseases that go well beyond any single indication. For Biogen, which has been managing the decline of its multiple sclerosis franchise for several years while searching for the next durable revenue pillar, a therapy with genuine multi-indication potential is exactly the kind of asset that earns the “pipeline-in-a-product” label. Whether felzartamab actually delivers on that characterization depends on what Phase 3 studies produce over the coming years, but the strategic motivation for locking down global rights now, before that evidence is in, is straightforward: if the data is good, fragmented rights are expensive to fix after the fact.

The upfront payment of $100 million is modest relative to the commercial potential that Biogen is signaling by doing the deal. The milestone structure, which scales to $750 million contingent on commercial performance, is structured to protect Biogen’s balance sheet during the long development runway ahead while rewarding TJ Biopharma if the China commercial launch succeeds. That contingency design also tells you something about how Biogen’s management is thinking about risk: the $100 million is a market-entry cost, the $750 million is a success tax.

Why is the Greater China Region so critical to the commercial case for felzartamab in kidney disease?

The epidemiological backdrop in China for the specific diseases felzartamab targets is unusually favorable. IgA nephropathy, the most common form of primary glomerulonephritis globally, represents a particular burden in young Chinese adults, where it is a leading cause of end-stage kidney disease. Primary membranous nephropathy has become a leading cause of adult nephrotic syndrome in China, with incidence rising and a meaningful proportion of patients at risk of progressing to kidney failure without effective intervention. Both conditions involve pathogenic antibody activity driven by CD38-positive plasma cells, which is precisely the mechanism that felzartamab is designed to interrupt.

China’s nephrology treatment environment also reflects structural underservice. Approved treatment options for both IgAN and PMN remain limited, and the standard of care for PMN in particular still involves immunosuppressants and chemotherapy, therapies that carry significant toxicity profiles and do not address the underlying immunological drivers. A therapy that can selectively deplete the relevant plasma cells while maintaining a manageable safety profile would fill a genuine clinical gap, not just compete for existing treatment share. Phase 2 data from the IGNAZ study in IgAN showed proteinuria reductions maintained at roughly 50% from baseline through month 24, more than 18 months after the final dose, a durability signal that matters considerably in a disease where sustained disease modification is the clinical goal.

Beyond IgAN and PMN, TJ Biopharma’s December 2024 Biologics License Application for felzartamab in multiple myeloma is currently under review by China’s National Medical Products Administration. That filing means Biogen is potentially inheriting a near-term commercial opportunity in oncology, not only a long-term immunology development pipeline. Regulatory approval for the myeloma indication in China would accelerate Biogen’s revenue timeline in the region substantially, although it would also require the company to compete against established CD38-targeting antibodies already entrenched in the myeloma space.

How does this deal fit into Biogen’s broader capital allocation and pipeline pivot toward immunology?

Biogen’s pipeline trajectory over the past two years has been consistently directional: reduce dependence on the declining MS franchise, invest in platforms where the company can build durable clinical differentiation, and do so at deal sizes that do not overwhelm the balance sheet. The company closed 2025 with $4.2 billion in cash and marketable securities, and its 2026 guidance projects a mid-single-digit decline in total revenue, largely driven by continued MS erosion. Against that backdrop, the $100 million China rights acquisition is not a bet-the-company transaction. It is a targeted, capital-efficient move to complete the global rights picture on an asset that is already in Phase 3, already generating clinical evidence, and already integrated into Biogen’s operational machinery through the existing international trial collaboration with TJ Biopharma.

The structure of the relationship matters here. TJ Biopharma joined Biogen-sponsored Phase 3 trials in IgAN and PMN in China as recently as April 2025. That history means the two companies have already worked through regulatory interface protocols, clinical site management logistics, and data-sharing frameworks. Biogen is not acquiring an unfamiliar partner’s asset and hoping to integrate it; it is formalizing and taking full ownership of a collaboration that was already operational. That distinction matters for execution risk assessment. Integration of a Chinese biotech partner in a geopolitically complex regulatory environment carries enough inherent complexity without also managing strategic misalignment.

The Wells Fargo upgrade to Overweight with a revised price target of $250 per share, issued on the same day as the announcement, suggests at least one institutional voice views the immunology pipeline, of which felzartamab is a central pillar, as meaningfully undervalued in the current share price. At approximately $183, Biogen’s stock remains well below both its 52-week high of $202.41 and the average analyst price target of around $207. The 3.6% single-session gain on the announcement suggests the market sees the deal as incrementally positive, though not transformative in isolation. The real valuation question is whether the Phase 3 readouts across AMR, IgAN, and PMN deliver data that justifies the broader multi-indication thesis.

What are the risks Biogen must navigate to extract full value from the China rights?

The regulatory risk is not trivial. China’s National Medical Products Administration has its own approval cadence, its own evidentiary standards, and its own geopolitical context for evaluating biologics from foreign-controlled manufacturers. Biogen is inheriting responsibility for post-approval commercialization if the myeloma BLA receives clearance, in addition to running the IgAN and PMN Phase 3 programs. That is a meaningful operational footprint to build or expand in a market where foreign pharmaceutical companies have found commercial execution considerably harder than regulatory approval.

Manufacturing dependency is another variable worth watching. Under the terms of the agreement, TJ Biopharma will continue to manufacture felzartamab for the multiple myeloma indication at its Hangzhou GMP facility. That arrangement is practical in the near term but means Biogen’s myeloma supply chain in China remains dependent on a partner that has now monetized its primary stake in the asset. Incentive alignment for manufacturing quality and continuity when the economic upside has shifted to Biogen is a structural question that supply chain due diligence should have addressed, but it remains a risk to monitor.

Competitive pressure in the kidney disease space is intensifying. The IgAN market across major geographies was valued at roughly $730 million in 2024 and is projected to grow at a compound annual growth rate above 30% through 2034, a trajectory that will attract multiple entrants. Biogen and felzartamab are not the only players pursuing CD38-mediated or plasma-cell-targeted approaches in this space, and competing therapies targeting BAFF and APRIL pathways are already showing strong efficacy signals in Phase 3. The window for felzartamab to establish a first-mover or best-in-class position across its targeted indications is not unlimited.

Finally, the geopolitical environment for US-China biotech deals bears watching. Regulatory review of biologics, data sovereignty considerations, and shifting trade and tariff dynamics all create background noise that can complicate timelines and commercial operations. Biogen is not entering China for the first time, but the heightened environment makes any new rights acquisition a commitment that carries country-level as well as clinical risk.

Key takeaways: What the Biogen-TJ Biopharma felzartamab deal means for pharma, investors, and China’s nephrology market

• Biogen now holds exclusive worldwide rights to felzartamab for the first time, eliminating the split-rights structure that complicated development coordination across the Greater China Region.
• The deal structure, $100 million upfront against $750 million in contingent milestones, is designed to minimize near-term capital exposure while preserving upside for TJ Biopharma if China commercialization succeeds.
• China is among the largest patient populations globally for both IgAN and PMN, conditions with limited current treatment options and substantial unmet clinical need, making the market entry rationale epidemiologically sound.
• A pending Biologics License Application for felzartamab in multiple myeloma, filed by TJ Biopharma with China’s National Medical Products Administration in December 2024, could deliver Biogen an earlier-than-expected revenue opportunity in the region if approved.
• Biogen inherits manufacturing dependency on TJ Biopharma for the myeloma indication at the Hangzhou facility, a supply chain arrangement that requires sustained attention as the commercial relationship evolves.
• The Wells Fargo upgrade to Overweight and the revised $250 price target signal growing institutional confidence in Biogen’s immunology pipeline, with felzartamab increasingly positioned as the flagship asset.
• The IgAN global market is projected to grow at above 30% CAGR through 2034, ensuring a competitive field with multiple entrants targeting similar mechanisms, making Phase 3 differentiation essential.
• TJ Biopharma’s exit validates its asset-light, fast-to-market model and leaves the company with cash and royalty participation to reinvest in its remaining pipeline, including AntibodyPLUS conjugate programs.
• Biogen’s parallel pursuit of the Apellis Pharmaceuticals acquisition for $5.6 billion signals an aggressive immunology and ophthalmology pivot that is being executed across multiple transactions simultaneously, raising integration execution risk.
• Felzartamab’s multi-indication potential across AMR, IgAN, PMN, and potentially additional immune-mediated conditions means Phase 3 readouts over the next two to three years will define whether Biogen’s immunology pivot delivers the revenue replacement it requires.